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The COVID-19 pandemic has greatly impacted the daily clinical practice of cardiologists and cardiovascular surgeons. Preparedness of
health workers and health services is crucial to tackle the enormous challenge posed by SARS-CoV-2 in wards, operating theatres, inten-
sive care units, and interventionist laboratories. This Clinical Review provides an overview of COVID-19 and focuses on relevant aspects
on prevention and management for specialists within the cardiovascular field.
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Introduction and scope of the
review
Case study 1: A 59-year-old male underwent cardiac surgery for
complicated prosthetic valve endocarditis on 13 March. The follow-
ing day, the referral hospital notified that the patient had been in con-
tact for 24 h with a confirmed case of a COVID-19. A
nasopharyngeal swab confirmed SARS-CoV-2 infection. The patient
developed bilateral pneumonia with ARDS and died on March 20.
The contact tracing revealed the patient had been in contact with 25
healthcare workers, one having become infected.
Takeaway: During the initial phases of the pandemic, while SARS-
CoV-2 is actively circulating within the community and the healthcare
system, systematic screening systematic screening for SARS-CoV-2
infection should be done in all transferred patients to avoid nosoco-
mial transmission.
COVID-19 is an illness caused by a novel coronavirus initially
called 2019-nCoV and currently named SARS-CoV-2. From
December 2019 to date, COVID-19 has attained a global dimension,
having been declared a pandemic by the World Health Organization
(WHO) on 11 March 2020.1 The outbreak started in the Chinese
city of Wuhan, Hubei Province, allegedly in the Central Market, and
rapidly spread. On 30 January the WHO declared the COVID-19
outbreak a global health emergency.1 To date (May 5), >3.5 million
SARS-CoV-2 infections and 250 000 deaths have been reported
worldwide.2 The pandemic has obliged many countries to enforce
strict control measures. They include home quarantines, lockdowns,
or severe limitations of air and road transport, telework, and others,
which have a deep impact on the global economy and people’s daily
life and well-being. Moreover, COVID-19 has led to a large overload
of health systems, especially at the hospital level, and has forced
health authorities and healthcare professionals to rapidly adapt to a
challenging and constantly changing situation. In some countries, hospi-
tals have turned into virtually solely COVID-19 centres. A new disease
far from being completely understood has totally challenged our
institutions and put the function of cardiovascular services at stake.
In this Clinical Review, we aim to provide a comprehensive sum-
mary of the most relevant characteristics of SARS-COV-2 and
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One-sentence summary: This review provides an overview and practical guidance for cardiologists and cardiovascular surgeons on the prevention, diagnosis, treatment, and prog-
nosis of COVID-19.
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COVID-19, as well as the specifics that cardiologists and cardiac sur-
geons must know in order to tackle prevention and treatment issues
involving their patients exposed to SARS-CoV-2.
Current epidemiology
As of today, the pandemic has undergone three main phases in terms
of geographical scope. From late December 2019 to mid-late
February, the main focus was Asia, with China having the highest con-
centration of outbreaks, followed by South Korea. After applying se-
vere containment measures, the dissemination has been controlled in
these countries and the second phase, still ongoing, affected
European countries from mid-February, Italy foremost followed by
Spain. The third phase started in mid-March and is characterized by a
pronounced increase in cases in the USA.2–5
Table 1 summarizes COVID-19 statistics in most affected
European countries as of 4 May 2020.
As regards baseline epidemiological characteristics, in China
COVID-19 affected mostly people aged 30–79 years (87%), whereas
cases over 80 years and below 19 years were relatively rare (3% and
2%, respectively).6 Mean age ranges from 47 to 56 years in the largest
reports, men are more likely to present COVID-19 (65% of cases),
15% of cases occur in smokers, and 25–30% of patients present
concomitant diseases, with up to 40% of these being cardiovascular
diseases, of which remarkably hypertension makes up 15–30%.7–9 A
recent meta-analysis found that hypertension, cardio-cerebrovascular
disease, and diabetes in patients with COVID-19 were present in
17.1, 16.4, and 9.7%, respectively.10 Healthcare workers are a group
at risk, with prevalence varying according to the setting, e.g. they rep-
resent 3.8% of infected individuals in China6 and 15.5% in Spain.11
The virus and pathogenesis
Coronaviruses are found in a variety of birds and mammals through-
out the world and have a proclivity for emergence. In the past 20
years, three novel human coronaviruses have emerged, first SARS-
CoV in 2002, Middle East respiratory syndrome (MERS)-CoV in
2012, and the causative agent of COVID-19, SARS-CoV-2, in 2019,
and all three are believed to have originated in bats.12–14 SARS-CoV-
2 is a beta-b coronavirus genetically related to but distinct from
SARS-CoV.15 To gain entry into the host cell, the SARS-CoV-2 S
glycoprotein binds the cellular receptor angiotensin-converting en-
zyme 2 (ACE2), which is also the receptor for the original SARS-
CoV.13 Figure 1 shows the life cycle of SARS-CoV-2.
SARS-CoV (basic reproduction number-R0 1.8–2.5), MERS-CoV,
and SARS-CoV-2 (R0 2.4–3.8) are primarily transmitted by the re-
spiratory route on large droplet nuclei, close contact with infected
people, or fomites. The main form of SARS-CoV-2 transmission is
person to person through respiratory droplets in the air (reaching up
to 2 m) and landing on surfaces, which can transmit the virus even
after several days.16,17 SARS-CoV-2 is the most infectious of the
three, with each case causing an estimated 2–4 new cases, whereas
the R0 of influenza virus varies according to the season from 1.2 to
2.14 Pre-symptomatic and first symptomatic days correlate with a
higher viral load, which has been proved to entail a higher risk of
transmission.18
The virus targets cells lining the respiratory epithelium, causing a
range of symptomology from asymptomatic infection to severe end-
stage lung disease requiring mechanical ventilation as for ARDS.14
Disease severity is likely to be a combination of direct virus-induced
pathology and the host inflammatory response to infection. In brief,
two mechanisms have been proposed for lung injury leading to
ARDS during coronavirus infections in humans. First, ACE2 not only
....................................................................................................................................................................................................................














infected [mean (95% CI)]5
Spain 217 466 25 264 118 902 465.1 11.6 15% (3.7–41%)
Italy 210 717 28 884 81 654 348.5 13.7 9.8% (3.2–26%)
UK 187 842 28 446 902 276.7 15.1 2.7% (1.2–5.4%)
France 168 925 24 864 50 885 258.8 14.7 3.0% (1.1–7.4%)
Germany 165 745 6866 132 700 197.8 4.1 0.72% (0.28–1.8%)
Belgium 50 267 7924 12 378 433.7 15.8 3.2% (1.3–7.6%)
Netherlands 40 968 5082 322 239.1 12.4 3.7% (1.3–9.7%)
Switzerland 29 981 1762 24 500 346.4 5.9 –
Portugal 25 524 1063 1712 250.3 4.2 1.1% (0.36–3.1%)
Ireland 21 506 1303 13 386 435.5 6.0 –
Total 1 118 941 131 458 321 507 – 11.7 –
Incidence estimates are calculated based on current population data from each country (https://www.worldometers.info/world-population/population-by-country/) relying on
data extracted from Johns Hopkins University Coronavirus Resource Center.2 https://coronavirus.jhu.edu/map.html
Data in the last column (mathematical estimates) come from the Imperial College report5 issued on 30 March 2020. https://www.imperial.ac.uk/media/imperial-college/medi
cine/sph/ide/gida-fellowships/Imperial-College-COVID19-Europe-estimates-and-NPI-impact-30-03-2020.pdf
To calculate the approximate incidence in each country, the 2020 population by country was found on the Worldometer webpage: https://www.worldometers.info/world-popu
lation/population-by-country/


























.acts as mediator of coronavirus entry into the cells, but also contrib-
utes to diffuse alveolar damage through imbalances in the renin–
angiotensin system due to its down-regulation, activated by the S
protein. Secondly, some coronavirus proteins are strong inducers of
apoptosis of cell lines derived from different organs, primarily the
lungs.19
Alveolar macrophages also play an important role, since their acti-
vation underlies the cytokine storm phenomenon: a massive release
of macrophage migration inhibitory factor (MIF), tumour necrosis fac-
tor (TNF)-a, and interleukin (IL)-1, IL-2R, IL-6, IL-8, and IL-10, attract-
ing neutrophils that will release leukotrienes, oxidants, and proteases,
which will lead to the typical ARDS pathology with acute diffuse al-
veolar damage, pulmonary oedema, and formation of hyaline
membranes.
In summary, there are two phases in SARS-CoV-2 infection: during
early infection (up to 7–10 days), viral syndrome predominates with a
high viral load in the upper and lower respiratory tract; in a second
phase, viral pneumonia can develop; and finally the viral infection can
trigger the host inflammatory and procoagulant responses with SIRS,
ARDS, shock, and cardiac failure (see Figure 2).
Pro-inflammatory and pro-
coagulant states as triggers of
cardiovascular events
ACE2 receptors are also located in the heart, kidney, brain, and gut,
and therefore COVID-19 might cause a plethora of extrapulmonary
manifestations, including cardiovascular ones.20 In the case of heart
injury, preliminary data indicate that pericytes with high expression of
ACE2 might act as the target cardiac cell of SARS-CoV-2 and, once
damaged, capillary endothelial cell dysfunction arises, inducing micro-
vascular dysfunction.21,22 In addition to the immune pathway, leading











































Figure 1 Life cycle of SARS-CoV-2 and potential medical countermeasures. The positive-sense RNA genome of SARS-CoV2 is encapsulated in a
viral envelope studded with four viral structural proteins: spike (S), envelope (E), membrane (M), and nucleocapsid (N). SARS-CoV-2 gains entry into
the host cell via binding of the S protein to the cellular receptor angiotensin-converting enzyme 2 (ACE2). Spike glycoprotein rearrangement that
primes fusion of viral and host membranes is driven by host proteases (TMPRSS2, cathepsins, HAT, furin, etc.), after which the genome is deposited
into the cytoplasm and translation of ORF1a/b ensues. The polyproteins generated from ORF1a/b are cleaved by viral proteases liberating 16 non-
structural proteins that guide virus replication. The replication complex is formed on double membrane vesicles, creating both genome-length RNA
as well as subgenomic RNAs that encode structure genes S, E, M, and N as well as accessory ORFs that probably play roles in modulating the host re-
sponse. New virus particles are assembled on membranes derived from the ER–Golgi complex and then transported out of the cell via the secretory
pathway. Medical countermeasures are shown in italics adjacent to the viral function they are thought to attack. Convalescent sera and neutralizing
monoclonal antibodies should inhibit virus binding to ACE2 and entry. Chloroquine is thought to interrupt entry and/or egress. Protease inhibitors
such as lopinavir/ritonavir are thought to prevent polyprotein proteolysis. Nucleoside analogues such as remdesivir and ribavirin are thought to pre-
vent viral RNA synthesis. *Interferons induce the expression of antiviral and immunomodulatory genes that could affect multiple aspects of the virus
replication cycle HCQ/CQ, hydroxychloroquine/chloroquine.
























































































arrhythmic events as a consequence of a pro-inflammatory cascade,
SARS-CoV-2 induces coagulation disorders that might also decom-
pensate pre-existing cardiovascular diseases.23 In brief, systemic
hyperinflammatory response, coagulation disorders involving pro-
thrombotic states, microvascular injury, stress cardiomyopathy, myo-
cardial injury secondary to oxygen supply–demand mismatch, and
acute coronary syndromes triggered by plaque instability are major
pathways for cardiovascular events in COVID-19 patients.21–30
Moreover, social distancing and social isolation as preventive meas-
ures also seem to increase cardiovascular risk.22
Clinical manifestations
The most common symptoms of COVID-19 are fever and dry cough,
together with shortness of breath (Table 2). More recently, anosmia,
hyposmia, and dysgeusia have also been described as largely charac-
teristic during the initial phase of COVID-19.31 Meanwhile, digestive
symptoms can also be found. Common blood test parameters in-
clude lymphocytopenia, increased IL-6, C-reactive protein (CRP), lac-
tate dehydrogenase (LDH), D-dimer, ferritin, transaminases, high-
sensitivity troponin, and N-terminal pro-brain natriuretic peptide
(NT-pro-BNP). Meanwhile, procalcitonin levels are usually very low,
which helps to differentiate COVID-19 from acute bacterial infection.
It should be noted that these parameters evolve dynamically through-
out the course of the disease: for instance, white blood cell count
often progresses from normal total counts with lymphocytopenia to
leukopenia in severe cases. Moreover, the neutrophil–lymphocyte
ratio appears to be associated with illness severity.32
Radiological manifestations range from normal chest X-ray or CT
scan in10% of cases to lung fibrosis.33 More commonly, COVID-19
presents as pneumonia (bilateral in around half of the cases) with re-
ticular nodular or ground-glass opacities.
Approximately 5–10% of patients require admission to the inten-
sive care unit (ICU) and mechanical ventilation.34 Among patients
with pneumonia, ICU admission is required in 23–26% of cases and
ARDS develops in 16–42% of them.8,9,14,35 Shock has been described
in up to 20% of cases,9 but most series range between 1% and 8%.
Figure 2 shows the different stages within COVID-19 natural his-
tory and their correlation with pathophysiology. Onset of pulmonary
symptoms occurs at the transition from a viral phase characterized
by high viral load and relatively low inflammation to a host inflamma-
tory response phase characterized by increasing inflammation and
coagulation disorders. Typically, complications appear around days
10–12 after initial symptoms, often related to the triggering of an in-
flammatory cascade leading to the ‘cytokine storm’.36
Cardiovascular manifestations
Table 3 shows a summary of the cardiovascular manifestations and
complications related to COVID-19, as well as the guidance launched
by scientific societies for their prevention and management. Although
empirical data are lacking and the prevalence of cardiovascular events
during and after COVID-19 has still not been described yet, it
appears that cardiovascular events, especially myocarditis, are rela-
tively common.37–44
Meanwhile, the COVID-19 pandemic seems to be associated with
a decrease in consultations pertaining to cardiovascular events in
non-COVID-19 patients. Studies from the USA, Italy, and Spain
showed approximate reductions of 40% in ST-segment elevation
myocardial infarction (STEMI) activations in cardiac catheterization
laboratories and significant reductions in hospitalization rates due to
acute coronary syndromes.45–47 The Italian report also described a
concomitant increase in mortality rates compared with the previous
year, which was not fully explained by COVID-19-related mortality,
therefore raising the question of whether some patients might have
died of acute coronary syndromes without seeking medical attention.
Regarding cardiac arrest, data from Lombardy in Italy showed an in-
crease of out-of-hospital cardiac arrest incidence strongly associated
with the cumulative incidence of COVID-19.48 A study from Wuhan
in China showed that survival of patients with COVID-19 suffering in-
hospital cardiac arrest was extremely low at 30 days (2.9%).49
Finally, it should be borne in mind that acute pulmonary injury can
potentially resemble pulmonary oedema, and thus differential diagno-
sis in patients with a prior history of heart failure is key, given
the associated therapeutic implications [e.g. bilevel positive
airway pressure (BiPAP) is to be avoided in COVID-19 patients]. The
same is applicable to COVID-19 patients presenting with chest pain
and elevated levels of troponin and to differentiating it from
myocarditis.
Diagnosis
Laboratory diagnosis is a priority for clinical management and out-
break control of COVID-19. Respiratory samples have the great-
est yield, but other specimens such as blood and stools can also
be used; however, evidence on their efficacy is lacking.50,51 Real-
time reverse-transcription polymerase chain reaction is the cur-
rent gold standard.50 Detection of total antibodies, IgM and IgG,
against SARS-CoV-2 in blood samples, may be non-sensitive dur-
ing the first 7–14 days of disease.52 Performing combined testing
strategies with PCR and antibodies increases sensitivity to 90%.51
Clinicians should consider testing for other respiratory patho-
gens using routine laboratory procedures if individual case man-
agement requires because both viral and bacterial co-infections
can occur.53 Yet, in the context of epidemics, patients with a clin-
ical presentation and radiological pattern that is compatible are
assumed to have COVID-19, despite a negative (or unavailable)
molecular or viral antigen detection test. However, clinical diagno-
sis should also take account of the clinical manifestations
described in most series being constrained by a major population
selection bias, with severe patients being more likely to be
included in the studies.
Prognosis focused on
cardiovascular risk factors
Older age is the most widely recognized epidemiological risk fac-
tor of mortality (Table 4). Mortality below 50 years is uncommon,
but thereafter it doubles in each decade of life, going from 2% in
the 50s to 16% or more in the 80s. Among comorbidities, hyper-
tension and diabetes are also found among patients presenting
poor outcomes, yet it should be noted that these both could be
correlated to advanced age. Li et al. found that the percentage of
patients with hypertension, cerebrovascular diseases, and diabetes

































was two-fold, three-fold, and two-fold higher, repspectively in
patients admitted to the ICU than in patients not presenting se-
vere or critical COVID-19, and that acute cardiac injury was also
13-fold higher in the former group of patients.10 Shi et al. also
found a 10-fold higher mortality among patients presenting with
cardiac injury in a cohort of 416 patients with COVID-19, and
predictors of cardiac injury included epidemiological (older age,
comorbidities), analytical (leukocytosis, CRP, procalcitonin, creat-
ine kinase, myohaemoglobin, high-sensitivity troponin I, NT-pro-
BNP, aspartate aminotansferase (AST), and creatinine], and higher
radiological (multiple mottling and ground-glass opacities).54 Other
studies have found that high levels of D-dimer, NT-pro-BNP,
and high-sensitivity troponin I are strongly associated with acute
cardiac injury and poor prognosis.38 More recently, Argulian and
colleagues found that right ventricular dilation in the echocardiog-
raphy is associated with an increased risk of in-hospital death in a
large series of patients hospitalized with COVID-19.55
High fever and dyspnoea on admission, and developing respira-
tory insufficiency have been commonly linked to poorer out-
comes, as have high levels of D-dimer, LDH, IL-6, and
transaminases, and low total lymphocyte count and CD3 and
CD4 T-cell counts. Bilateral lung involvement as opposed to uni-
lateral involvement does not seem to be associated with poorer
mortality in most studies, yet Zhang et al. found that multilobar




Currently there are no approved therapies specific to human corona-
virus, and multiple medical countermeasures including direct acting
antivirals (DAAs), host-targeted antivirals, and immunomodulators
are being prescribed off-label for treating COVID-19 based on past
observational studies for other coronaviruses as an attempt to dimin-
ish disease severity.57 In addition, multiple therapies are currently
being evaluated in randomized control trials to conclusively deter-
mine efficacy,58,59 with >300 registered trials ongoing related to
COVID-19.60
Table 5 shows a summary of the drugs utilized and proposed for
treating COVID-19 to date.
Figure 2 Clinical stages of COVID-19 (adapted with permission from Siddiqu and Mehra125). During the first days from disease onset, patients typ-
ically present a first phase with symptoms resembling an upper respiratory tract viral infection, mostly characterized by fever and coughing. Over
days 8–12 there is a transition to an inflammatory phase during which pulmonary symptoms such as shortness of breath might appear. In those
patients progressing to the hyperinflammatory phase with relevant lung involvement, the risk of ARDS is notable. In addition, during this late phase,
patients are at higher risk of suffering thrombotic and embolic events due to a procoagulant state. ARDS, acute respiratory distress syndrome; CRP,
C-reactive protein; IL-1, interleukin 1; IL-6, interleukin 6; LDH, lactate dehydrogenase; NT-pro-BNP, natriuretic pro-brain natriuretic peptide; SIRS,
systemic inflammatory response syndrome.
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Table 3 Cardiovascular manifestations in COVID-19
Study Type of study Country Main findings
Original studies and case reports
Shi et al.54 Prospective cohort China 82/416 (19.7%) patients presented cardiac injury.
Deng et al.37 Retrospective study of 112 patients with
COVID-19
China 14 (12.5%) presented abnormalities similar to myo-
carditis, but without typical signs on echocardi-
ography and electrocardiogram.
Gao et al.38 Retrospective, observational registry of
102 patients with severe COVID-19,
only 54 of whom entered the analysis
(NCT04292964)
China Patients with high NT-pro-BNP values (>88.64 pg/
mL) had a significantly increased risk of death
during follow-up
Bangalore et al.39 Cases series of 18 patients USA 18 patients with COVID-19 presenting with ST-seg-
ment elevation, 10 of whom had non-coronary
myocardial injury
Sala et al.40 Case report Italy Acute myocarditis presenting as a reverse Tako-
Tsubo syndrome
Dong et al.41 Series of four cases China Four patients with prior cardiovascular (CV) dis-
ease developed end-stage heart failure during
COVID-19 (2 of them died).
Zeng et al.42 Case report China Fulminant myocarditis
Kim et al.43 Case report China Myocarditis in a 21-year-old patient
Zhang et al.44 Series of three cases China Coagulopathy and antiphospholipid antibodies
Reviews and perspectives
Xiong et al.24 Narrative review China, UK Coronaviruses, including SARS and MERS, have
short- and long-term implications for the CV sys-
tem. Patients presenting with CV manifestations
seem to more frequently require ICU admission.
Madjid et al.25 Narrative review USA Acute cardiac injury determined by elevated high-
sensitivity troponin levels is commonly observed
in severe cases and is strongly associated with
mortality
Driggin et al.26 Narrative review USA Patients with CV comorbidities more frequently re-
quire ICU admission. COVID-19 can lead to ex-
acerbation of previous CV disease or to specific
complications such as myocardial injury, myocar-
ditis, and acute coronary syndromes, cardiogenic
shock, or arrhythmia.
Liu et al.27 Narrative review USA The CV system is commonly involved in early
phases of COVID-19. Microangiopathy and
thrombosis seem to be the main mechanisms of
cardiac injury. Levels of hsTrP and NPs are
prognostic.
Kochi et al.28 Narrative review Italy and Switzerland Close monitoring of potential arrhythmogenic
effects of both COVID-19 itself and antiviral
medication is advisable, especially in patients
with previous CV disease.
Libby29 Short review and perspective USA There are likely to be multiple pathophysiological
pathways involved in cardiac injury during
COVID-19, which call for precaution in deciding
therapeutic approaches until more robust evi-
dence is available
Guidance
Edelson et al.97 Guidelines USA Interim guidance for basic and advanced life
support
Continued












































The drugs currently under exploration are thought to target vari-
ous aspects of the virus life cycle (Figure 1). The objectives of treat-
ment are three-fold (Figure 2): first, to administer an early antiviral
treatment that will be more effective on the first 7–14 days of infec-
tion, which is when the viral load is highest in the upper and lower re-
spiratory tract; secondly, to address the cytokine storm in order to
prevent onset of ARDS and avoid the need for mechanical ventila-
tion, which has a mortality of 50%; and, thirdly, to reduce the likeli-
hood of major thrombo-embolic events.
Case study 2: A 43-year-old male with a history of non-
compaction cardiomyopathy bearing an implantable cardioverter de-
fibrillator for primary prevention of sudden cardiac death underwent
cardiac transplantation on 3 March. During the post-operative
period, the patient shared nursing staff with a patient who several
days later tested positive for SARS-CoV-2. On 16 March, he tested
positive for SARS-CoV-2, developing a moderate COVID-19 pneu-
monia. The contact tracing revealed 10 exposures but no secondary
cases. Corticosteroids were maintained at 0.5 mg/kg and tacrolimus
was stopped during the 10-day lopinavir/ritonavir therapy.
Tacrolimus serum levels evolved from 20 to 15 ng/mL during the 10-
day period off the drug (the patient also received hydroxychloro-
quine and azithromycin without significant QT prolongation). He
evolved well in a general ward and was discharged.
Takeaway: Nosocomial SARS-CoV-2 infection is possible and
some antiviral SARS-CoV-2 therapies have significant pharmacoki-
netic and pharmacodynamic (QT prolongation) interactions.
Hydroxychloroquine alone or combined with azithromycin, lopi-
navir/ritonavir, and remdesivir has been the most used off-label
antiviral drugs. Hydroxychloroquine and chloroquine alone or com-
bined with azithromycin may increase in hospital mortality and the
risk of ventricular arrhythmia due to QT prolongation,61,62 and their
use is currently not recommended outside of clinical trials.63
Lopinavir/ritonavir may also increase the QTc interval, has significant
drug–drug interactions (as shown in case study 2) and side effects,
and a randomized clinical trial did not show efficacy.64 Performance
of an ECG is mandatory and periodic ECG monitoring should be con-
sidered in patients taking these drugs. Remdesivir was recently
approved (1 May) by the US FDA for an emergency use authorization
for the treatment of suspected or laboratory-confirmed COVID-19
in adults and children hospitalized with severe disease.65–67 The
Liverpool web page periodically updates drug interactions with
COVID-19 medications (www.covid19-druginteractions.org).68
Routine use of systemic corticosteroids is not recommended for
preventing or treating ARDS in COVID-19 patients unless they are
indicated for other reasons.69,70 Preliminary studies with IL-6 inhibi-
tors (e.g. tocilizumab, see Table 5) have shown efficacy in patients
with severe or critical COVID-19.71,72 The use of corticosteroids or
other anti-inflammatories is recommended in the context of clinical
trials. Due to the procoagulant state caused by SARS-CoV-2, sub-
cutaneous low molecular weight heparin prophylaxis is recom-
mended for all hospitalized patients if there is no contraindication.73
Weight-adjusted intermediate doses of heparin are recommended in
patients with risk factors for venous thrombo-embolism, and patients
with thrombo-embolic disease must be fully anticoagulated.73
Given the initial evidence pointing to a higher mortality in patients
with hypertension,9,35 there has been a discussion, mainly generated
....................................................................................................................................................................................................................
Table 3 Continued
Study Type of study Country Main findings
Han et al.89 Experts consensus China Clinical management of patients with severe emer-
gent CV diseases
Welt et al.90 Consensus statement USA Catheterization laboratory considerations
Romaguera et al.88 Consensus statement Spain Considerations on the invasive management of is-
chaemic and structural heart disease during the
COVID-19 coronavirus outbreak
Hunt et al.98 Living guidance (updated weekly) UK Prevention of thrombosis and management of coa-
gulopathy and disseminated intravascular coagu-
lation of patients infected with COVID-19
Zhai et al.99 Consensus statement China Prevention and treatment of venous thrombo-
embolism associated to COVID-19
Zhai et al.88 Consensus statement China Prevention and treatment of venous thrombo-
embolism
Wood et al.93 Summary of guidance from professional
societies (North American Society
Leadership)
USA Safe reintroduction of cardiovascular services
European Society of Cardiology Special section on website Europe https://www.escardio.org/Education/COVID-19-
and-Cardiology
American Heart Association Special section on website USA https://www.heart.org/en/coronavirus
American College of Cardiology COVID-19 hub on website USA https://www.acc.org/latest-in-cardiology/features/
accs-coronavirus-disease-2019-covid-19-hub









through the media, regarding the necessity of avoiding the use of
ACE inhibitors and angiotensin receptor blockers (ARBs) to increase
the risk of infection and the severity of COVID-19. However, avail-
able evidence indicates that neither likelihood of contracting
COVID-19 nor mortality is increased in patients receiving those
drugs.74–77 On 13 March, the Council on Hypertension of the
European Society of Cardiology launched a statement strongly rec-
ommending that physicians and patients should continue treatment
with their usual antihypertensive therapy.78 More recently, a special
Task Force within the European Society of Hypertension critically
....................................................................................................................................................................................................................
Table 4 Summary of studies assessing prognostic factors of mortality and complications in COVID-19
Study Sample size Endpoint/s Risk factors Protective factors
Zhou et al.13 191 In-hospital death Older age, higher SOFA score, and high D-dimer
greater on admission
–
Wang et al.14 138 ICU admission Older age, comorbidities, dyspnoea –
Yang et al.100 52, all admitted
to ICU
In-hospital death Older age, ARDS, mechanical ventilation –
Zhang et al.56 645 Severe/critical COVID-19
categories
Myalgia, dyspnoea, nausea and vomiting, lymphocy-
topenia, higher creatinine and number of lobes
radiologically involved at admission
–
Shi et al.54 416 Cardiac injury (associated
with higher in-hospital
death)
Older age, more comorbidities, higher leucocyte
counts, higher levels of C-reactive protein, procal-
citonin, CK-MB, myohaemoglobin, high-sensitivity
troponin I, NT-pro-BNP, AST, and creatinine, and
higher proportion of multiple mottling and
ground-glass opacity
–
Wu et al.35 201 ARDS and progression to
death in patients with
ARDS
ARDS: older age, high fever, comorbidities, neutro-
philia, lymphocytopenia (as well as lower CD3
and CD4 T-cell counts), elevated end-organ-
related indices (e.g. AST, urea, LDH), elevated in-
flammation-related indices (high-sensitivity C-re-
active protein and serum ferritin), and elevated
coagulation function-related indicators (pro-
thrombin time and D-dimer).Death in ARDS:
older age, lower proportion of high fever, hyper-
tension, neutrophilia, elevated bilirubin, urea,
LDH, D-dimer, cystatin C, and IL-6.




Huang et al.101 41 ICU admission Dyspnoea, neutrophilia, lymphocytopenia, enlarged
prothrombin time, elevated D-dimer, transami-
nases, bilirubin, troponin I, IL-2, IL-7, IL-10, GSCF,
IP10, MCP1, MIP1A, and TNFa, and lower
albumin
High fever
Liu et al.102 78 Clinical deterioration, and
likeliness of high-level
respiratory support
Older age, history of smoking, high fever, respiratory
failure, low albumin, high C-reactive protein
–
Sun et al.103 600 Progression to critical
condition
Older age, lymphocytopenia, oxygen supplementa-
tion and multiple/extensive pulmonary radio-
graphic infiltrations
–
Mo et al.104 155 Refractory pneumonia* Male sex, anorexia, and high fever at admission,
receiving oxygen, expectorants, corticosteroids,
lopinavir/ritonavir, immune enhancer (thymalfasin,
immunoglobulins)
–
Wang et al.105 68 SpO2 <90% (related to
death)
Older age, comorbidities, elevated IL-6, IL-10, LDH,
and C-reactive protein
–
*Defined as those cases not fulfilling all the following: (i) obvious alleviation of respiratory symptoms (e.g. cough, chest distress. and shortness of breath) after treatment; (ii)
maintenance of normal body temperature for >_3 days without the use of corticosteroids or antipyretics; (iii) improvement in radiological abnormalities on chest CT or X-ray
after treatment; and (iv) a hospital stay of <_10 days.











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































reviewed the available evidence and came to the conclusion that it
does not support a deleterious effect of renin–angiotensin blockers
in COVID-19, observing increased lower respiratory tract infections
and lung injury.79 Moreover, Zhang et al. recently reported a
significantly lower mortality rate among patients with hypertension
receiving ACE inhibitors or ARBs during admission compared with
other patients with hypertension hospitalized due to COVID-19.80
Based on the knowledge of SARS-CoV-2 pathogenicity traits, some
authors advocate conducting studies to test the efficacy of both
ARBs and statins to treat severe COVID-19, arguing that up-
regulated ACE2 receptor activity is associated with a reduced
severity of ARDS.81 There are currently two trials including patients
without hypertension that are testing losartan (NCT04312009 and
NCT04311177).60
Finally, there are some important points to be made for cardiovas-
cular specialists regarding the management of critically ill patients in
the context of COVID-19. First, due to general hospital overload and
relative lack of ventilators, the avoidance of intubation in non-
COVID-19 patients becomes even more relevant than usual.
Secondly, differentiating patients with acute lung injury due to
COVID-19 from patients with acute pulmonary oedema due to heart
failure is crucial, since BiPAP should be avoided in the former.
Thirdly, high-flow nasal cannula oxygen should be used in an effort to
minimize alveolar injury prior to proceeding with intubation. Finally,
where oro-tracheal intubation and mechanical ventilation are
required, protective ventilation with relatively high pressures at the
end of the expiratory period and low volumes is recommended.34,69
Prevention adapted to Cardiology
and Cardiovascular Surgery
Once a first imported case of COVID-19 is confirmed and
isolated, the potential for further exponential disease spread within
the hospital and region is possible. Containment measures by
tracking of contacts and quarantine are necessary to mitigate the risk
of losing track of potentially infected individuals.82 Increasing preven-
tion practices in the hospital needs to be supported to a scale that ini-
tially may seem draconian to employees and healthcare providers. The
risk of internal disease spread puts not only patients at risk, but also
co-workers and their families, and ultimately the whole of society.
Facemasks should be used by all infected patients to avoid trans-
mission. Therefore, isolation of suspected or confirmed contagious
individuals is mandatory in any instance within the hospital with the
physical ability to avoid propagation of the virus. Healthcare person-
nel need to adopt appropriate protective measures and avoid cross-
contamination to other patients or co-workers. In this regard, pre-
ventive measures may continue to escalate within the hospital, for ex-
ample to conventional surgical masks for non-suspicious personnel
and patients, cancellation of face-to-face meetings, and so on.82
Furthermore, surfaces (fomites) must be disinfected, and therefore
frequent hand washing with soap and water is mandatory.
Full personal protection equipment (PPE) should be used following
established protocols after appropriate training. PPE for healthcare
professionals involved in the direct care of COVID-19 patients in-
clude the following elements: FFP3 respirators (filtering at least 99%
of airborne particles)—FFP2 and N95 respirators (filtering 94% and
95% of particles, respectively) can be used if FFP3 are not available—
fluid-resistant surgical masks (type IIR) provide barrier protection
against droplets; goggles, full face shield, or visor, or polycarbonate
safety spectacles for eye and face protection; gowns should be long
sleeved and disposable; gloves; and fluid repellent.82,83
In addition to droplet and contact precautions, allocating COVID-
19 (confirmed or suspected) patients in ICU cubicles with negative
pressure to avoid propagation of the virus through aerosols that could
reach outside the room and spread into clear areas should be pur-
sued. In general terms, careful patient screening during urgent/emer-
gent procedures is required, and adoption of full protection by means
of meticulous donning and doffing of PPE needs to be considered
along with staffing modifications. Also rescheduling of all non-urgent,
elective procedures seems justified in order to avoid environmental
and provider contamination. This underlines the need to develop indi-
vidualized contingency plans, adapted to each cardiovascular team,
and in a forward-looking way, i.e. with both the active epidemic phase
and the progressive resumption of clinical and surgical activities in
mind. These plans should be continuously updated. Managerial deci-
sions and team coordination should rely on an increased use of virtual
communication as opposed to face-to-face meetings. To prevent new
infections involving either patients or staff, tailored triage systems
largely based on telemedicine for programmed patients are of upmost
importance, along with the set up of clean and dirty zones.84,85 The
latter should have all the appropriate protection measures. Patients
should be allocated to the latter areas where there is evidence for the
reasonable suspicion of infection or contact with infected individuals.
It is advisable to perform all urgent procedures in specially equipped
areas on the assumption that patients are infected.
When a new case is detected within the hospital, contact tracing
includes other patients, staff, and close contacts before admission in
cases where there is suspicion of community acquisition rather than
nosocomial. The preventive medicine service and infection control
units carry out surveys to identify contacts and perform tests on
them. High-risk contacts among healthcare personnel imply pre-
emptive isolation. Figure 3 (Summarizing Illustration) shows a pro-
posal of prevention measures in different hospital settings providing
care to cardiovascular patients.
The operating room and the
catheterization/electrophysiology labs
Case study 3: A 65-year-old male was admitted for a STEMI code
on 11 March. An urgent angiography showed severe stenosis of
the proximal left anterior descending artery, which was treated
percutaneously with a drug-eluting stent in the haemodynamic la-
boratory. On 19 March, he developed a moderate COVID-19
pneumonia. Contact tracing revealed 20 contacts but no secondary
cases in coronary and cardiology units. The patient was successfully
treated and discharged to a convalescence centre 14 days later.
However, the three staff members of the haemodynamic laboratory
developed COVID-19.
Takeaway: When urgent screening for SARS-CoV-2 infection
cannot be performed, appropriate PPE must be used. In addition,
acute coronary syndrome could be indirectly related to COVID-19.
An operating room with a negative pressure setting located as far
away as possible from other operating rooms, with separate access,





















is recommended for suspected or confirmed COVID-19 patients.86
Full PPE should be worn in compliance with current recommenda-
tions (including an N95 or FFP3 mask). If negative pressure environ-
ments are not available, the operating room doors should be kept
closed to avoid airborne spreading of the virus. This applies to any
interventional cardiovascular procedure. However, specific problems
can be encountered in cardiac surgeries requiring surgical field magni-
fication loupes that may compromise compliance with protective
recommendations. In this scenario, other forms of myocardial revas-
cularization may be preferable.
For catheterization suites, the conventional emergent transfer
for diagnostic/therapeutic purposes has been questioned during
the pandemic situation, and proposals to screen every single
patient for COVID-19, regardless of delay in therapy, have been
adopted by some practitioners.87,88 The consensus is that percu-
taneous coronary intervention (PCI) remains the first option ex-
cept for cases of severe COVID-19. This strategy may apply to
any non-emergent cardiac surgery. The need to individualize
decisions gains relevance in this context.89,90 When in doubt, if
the situation does not allow for confirmatory tests, the recom-
mendation should be to proceed with full PPE and adopt all
strategies as when dealing with a confirmed COVID-19 patient.
Any other non-urgent/emergent procedure which merits full in-
vestigation and systematic screening prior to invasive procedures
may ultimately be indicated to prevent some of the exposed
clinical issues here.
Negative pressure rooms **
Mask at all times at clean spaces
Hand hygiene
Full PPE and FFP3 or N95 masks inside the COVID-19 room
Avoidance if possible of transfers. Bedside procedures
Avoid interaction from personnel working in COVID-19
 units into non-COVID-19 units
Consider creating multidisciplinary teams that work
 together in turns and minimize interaction
Clean machines and probes after use and before storage
Minimize contacts. Restrict family/relatives visits
Dedicated COVID-19 and non-COVID-19 units
Dedicated COVID-19 and non-COVID-19 units
Mask at all times at clean spaces
Hand hygiene
Full PPE and FFP3 or N95 masks inside the COVID-19 room
Patients remain inside room. No ambulation outside
Avoid interaction from personnel working in COVID-19
 units into non-COVID-19 units
Minimize contacts. Restrict family/relatives visits
Isolation and relocation of new cases
Very early discharge from the hospital
Prevention of further cases. Rule out if patient can infect
others when discharged and take appropriate measures
ICU measures (negative pressure room) Regular ward
Bed
coordinator
Limit in-person consultation and visits
Use telehealth to interact with coworkers
Use telehealth to interact with patients if sufficient
Telehealth if feasible
Defer all possible activity to focus on pandemic support
Reschedule visits and counseling to confined patients
In patient consultation Outpatient visits
COVID-19
pandemia
Negative pressure rooms if possible
Full PPE and FFP3 or N95 masks 
Suite located away from other operating rooms
Minimize staff inside suite
Cancel elective procedures
Defer all non-emergent procedure until COVID-19
 clearance is obtained
Consider alternative non-operative management 
 options for disease
Full PPE before starting resuscitation
FFP3 or N95 masks before resuscitation
Intubation carried by most experienced airway operator
Mechanical chest compression devices consideration
Higher threshold to establish ECMO support
 in this context
Ensure family information and feedback
If possible facilitate patient-family online communication
Operating rooms and catheterization/
electrophysiology labs
Cardiac arrest management for
COVID-19 patient
Consider managing ALL patients (even if PCR negative)
as potential COVID-19  patients and take measures
Ensure that cardiovascular patients requiring
emergent care are not left unattended
Scheme in the setting of COVID-19 pandemic
**Figure number 3 depics proposed professional environments for ICUs without negative pressure rooms
Figure 3 Proposed scheme of prevention measures in different settings involving cardiovascular patients during the COVID-19 pandemic. ECMO,
extracorporeal membrane oxygenation; PPE, personal protective equipment.










































..Special considerations for management of
cardiovascular emergencies in confirmed
or suspected COVID-19 patients
While it is crucial that prevention measures, especially in the ICU, do
not compromise appropriate monitoring and timely therapeutic ac-
tion, it is also of outstanding importance to avoid healthcare workers
and other patients being infected due to the lack of appropriate
actions taken during a cardiovascular emergency. Prevention and
control of COVID-19 transmission should be adopted as the highest
priority, including self-protection of medical staff.82 If possible, inva-
sive procedures should be replaced by more conservative ones while
aiming for the best possible patient outcomes. Also, minimizing trans-
fers within the hospital is recommended, and therefore all tests and
procedures should be performed at the bedside if feasible. Figure 4
shows a proposed organization of ICU areas to minimize spread of
the virus among patients and staff.
During a cardiac arrest, PPE needs to be worn by all members of the
resuscitation team. Prolonged facemask ventilation should be avoided
to decrease the amount of aerosol generation. Consideration should
be given to using automated chest compression devices to minimize
contact. Intubation and chest compressions should be delayed until
fully equipped personnel with PPE become ready to interact safely.89
Burdens of operability in a COVID-19
environment
The burdens of cardiac operability, procedural choice, and best re-
source allocation during a pandemic outbreak may remain debatable
and are under investigation. A delay in emergent life-threatening con-
ditions requiring cardiac surgery is not justified unless restrictive cri-
teria (limitation to ICU acceptance) are applied to the entire
healthcare system. Fortunately, the majority of patients with severe
forms of heart disease may tolerate a delay of weeks to months
under best medical treatment. Estimates of hospital occupancy
and availability of resources need to be frequently revisited with the
intention of reallocating these patients into the surgical schedule
as soon as possible. For urgent conditions that cannot be delayed
(most frequently unstable coronary disease), alternative modalities of
treatment may be given priority despite different existing guideline
recommendations. In the transplant arena and due to a perceived
increased risk of complications in such patients, it may be justifiable
to accept a ‘programme lock down’ period for elective heart
transplantation.
Allocation of resources and service
preservation in cardiovascular
departments
Care for non-COVID-19 patients must continue despite the extreme
pressures to which many European healthcare systems have been
exposed. Cardiac surgery departments have a responsibility to their
patients that may have been compromised, in a large number of prac-
tices, during the pandemic. This may have happened as a result of re-
allocation of hospital resources or due to maintaining unaltered
practices in healthcare environments that were not safe, resulting in













Full PPE and FFP3
Transition zonesClean areas
Figure 4 Proposed organization of an ICU during the COVID-19 pandemic (see text for explanation). FFP3, filtering facepiece protection 3; PPE,
personal protective equipment.
























































































highly specialized practices could make sense as long as the pandemic
situation does not force the system to use all its assets. The proposed
clustered or high-intensity staffing models could maintain operability
throughout part of the crisis if containment measures towards the
COVID-19 pandemic does not collapse the healthcare system.91
Such teams would be designed to cluster an attending physician, a
cardiovascular resident or fellow, two to three nurses, and anesthesi-
ologists. The teams would remain available and together until one
member becomes infected (or under suspicion of infection). The
workload would be distributed to a number of clustered teams to
provide a full operative service. Maintaining certain physicians with a
particular unique skill set (e.g. interventional cardiologists and cardiac
surgeons) working away from the frontline services may be reason-
able when the system can still compensate for their absence without
imposing a downgrade of care to COVID-19 patients. In the event
the system becomes overwhelmed due to a lack of manpower, such
physicians should be prepared to commit the full spectrum of their
skills and capabilities to mitigate the consequences of a pandemic.92
Reintroducing cardiovascular services
after COVID-19
Once the peak of COVID-19 is overcome in a particular setting, the
safe reintroduction of cardiovascular services requires close collab-
oration between public health officials and health systems. It is to be
noted that different invasive procedures and diagnostic tests might be
at different levels of re-escalation within a given region depending on
local COVID-19 penetrance and infrastructure requirements. The
process of reincorporating cardiovascular services is dynamic and the
capacity to manage a potential second wave of COVID-19 should be
maintained while there is still a risk of a second surge.93
Conclusions
The COVID-19 pandemic is largely and rapidly affecting daily clinical
practice, and cardiologists and cardiovascular surgeons are not ex-
empt. Being aware of and updated on how SARS-CoV-2 is transmit-
ted, how it can be prevented, and who should be screened for
infection is currently crucial for the exercise of professional duties.
Also, all clinicians should be able to identify early clinical manifesta-
tions of COVID-19, including cardiovascular complications, and
therapeutic options as well as potential interactions with cardiovas-
cular drugs should be well known.
From a professional standpoint it seems wise to build a strong,
straightforward, coordinated, and anticipated response during the ini-
tial phase of disease locally. Early implementation of exponential pre-
ventive measures by means of universal use of masks, minimization of
personnel/patient and co-worker interaction, along with rescheduling
non-urgent consultations and surgeries, may facilitate better institu-
tional preparation for the peak caseload.
Alignment of regulatory bodies, healthcare institutions, clinical
services, and individual professional initiatives in the right direction
could allow avoidance of unnecessary mortality and complications
related to severe forms of COVID-19 in the general population and
early after cardiovascular procedures.
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